Contrasting of Replimune Group Inc. (REPL) and Recro Pharma Inc. (NASDAQ:REPH)

Replimune Group Inc. (NASDAQ:REPL) and Recro Pharma Inc. (NASDAQ:REPH) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Replimune Group Inc. N/A 0.00 31.03M -0.99 0.00
Recro Pharma Inc. 82.87M 2.43 69.25M -3.83 0.00

Demonstrates Replimune Group Inc. and Recro Pharma Inc. earnings per share, top-line revenue and valuation.


Table 2 provides us the net margins, return on equity and return on assets of both companies.

Net Margins Return on Equity Return on Assets
Replimune Group Inc. 0.00% -54.8% -28.8%
Recro Pharma Inc. -83.56% -580% -36.2%


38.1 and 38.1 are the respective Current Ratio and a Quick Ratio of Replimune Group Inc. Its rival Recro Pharma Inc.’s Current and Quick Ratios are 2.5 and 2.1 respectively. Replimune Group Inc. has a better chance of clearing its pay short and long-term debts than Recro Pharma Inc.

Analyst Ratings

The next table highlights the given recommendations and ratings for Replimune Group Inc. and Recro Pharma Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Replimune Group Inc. 0 0 0 0.00
Recro Pharma Inc. 0 1 3 2.75

Competitively Recro Pharma Inc. has an average price target of $8.5, with potential downside of -6.39%.

Insider and Institutional Ownership

Replimune Group Inc. and Recro Pharma Inc. has shares owned by institutional investors as follows: 90.6% and 70.9%. Insiders owned 12.4% of Replimune Group Inc. shares. Comparatively, insiders own roughly 1.3% of Recro Pharma Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Replimune Group Inc. -10.39% 9.82% 2.65% -0.69% 0% 43.1%
Recro Pharma Inc. 5.5% 12.04% 9.94% 27.89% -15.54% 32.39%

For the past year Replimune Group Inc. has stronger performance than Recro Pharma Inc.


Replimune Group Inc. beats Recro Pharma Inc. on 7 of the 10 factors.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. Its lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. The company also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain. It also provides contract development and manufacturing services. It has a license agreement with Orion Corporation for the development and commercialization of Non-Injectable Dexmedetomidine. The company focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.